Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo pill showdown: which diabetes cocktail wins?

NCT ID NCT07442006

Disease control Sponsor: JW Pharmaceutical Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests four different drug combinations in 178 adults with type 2 diabetes whose blood sugar is not well controlled on metformin and an SGLT-2 inhibitor. Over 12 weeks, researchers will measure how much and how often blood sugar swings. The goal is to find which combo offers the steadiest glucose levels.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Empagliflozin/Metformin, Anagliptin, Metformin, Empagliflozin/Linagliptin
What this could lead to
If successful, this could show which drug combination best stabilizes blood sugar and improves daily glucose control for people with type 2 diabetes.
What could go wrong
This is a mid-stage trial with only 178 participants over 12 weeks, so results may not apply to everyone. Side effects like kidney issues or metabolic acidosis are possible.
Why investors are watching

JW Pharmaceutical is running a Phase 4 trial in 178 people with type 2 diabetes to compare how well different combination therapies control blood sugar swings. For a small company, this readout matters because a positive result could give its drug combination a clearer place in standard diabetes care, while a negative one would leave the product without a strong selling point.

If it works: A positive result could support wider use of the combination therapy and give JW Pharmaceutical a concrete advantage to discuss with doctors and payers. That could strengthen the product's commercial position without any guarantee of sales growth.

If it fails: Phase 4 trials often fail to show a meaningful difference, and a negative or unclear result could weaken confidence in the drug's value. Delays in enrollment or data readout would also push back any potential benefit.

AI-written from the trial record. Speculative, and not investment advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 178 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Inadequate glycemic control despite treatment with Metformin (≥ 1,000mg/day) and SGLT-2 inhibitor. Exclusion Criteria: * History of acute or chronic metabolic acidosis * Moderate to severe renal impairment (eGFR \< 45 mL/min/1.73m²) * Severe hepatic impairment * History of heart failure (NYHA Class III/IV)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 2 diabetes mellitus (T2DM) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 2 diabetes mellitus (T2DM)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The Catholic University of Korea, Bucheon St. Mary's Hospital, Principal Investigator

    RECRUITING

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.